排序方式： 共有3条查询结果，搜索用时 0 毫秒
1
1.
Jiang Tao Song Jiangdian Wang Xiaoyu Niu Shuxian Zhao Nannan Dong Yue Wang Xingling Luo Yahong Jiang Xiran 《Molecular imaging and biology》2022,24(4):550-559
Molecular Imaging and Biology - To noninvasively evaluate the use of intratumoral and peritumoral regions from full-field digital mammography (DM), digital breast tomosynthesis (DBT), dynamic... 相似文献
2.
3.
Tommy Tsang Cheung Joanne Wing Yan Chiu Man Fung Yuen Karen Siu Ling Lam Bernard Man Yung Cheung Hwa-Ping Feng Wendy W. Yeh Jiangdian Wang Wenting Li Xu Min Zhao Zaiqi Wang Shengmei Mu 《Clinical therapeutics》2018,40(5):719-732.e1
Purpose
This study evaluated the single- and multiple-dose pharmacokinetic (PK) variables of elbasvir and grazoprevir in healthy Chinese individuals.Methods
This study was a 2-part, parallel-arm, open-label trial. In part 1, single-dose PK variables of elbasvir 10/50/100 mg and grazoprevir 50/100/200 mg were evaluated in 10 participants per drug. In part 2, 10-day multiple-dose PK variables of elbasvir 50 mg and grazoprevir 100 mg administered once daily alone and in combination were evaluated in 12 participants. Summary and inferential statistics of the PK parameters are reported. Elbasvir and grazoprevir PK parameters were also compared between Chinese participants and historical data from white participants.Findings
Single-dose elbasvir and grazoprevir median Tmax were 2.9 to 4.0 and 1.9 to 3.0 hours after administration, respectively. Elbasvir AUC0–∞ and Cmax increased in a dose-proportional manner (slope estimate [90% CI], 0.92 [0.84–1.01] and 0.98 [0.86–1.09], respectively), whereas grazoprevir AUC0–∞ and Cmax increased in a greater-than-dose-proportional manner (slope estimate [90% CI], 1.42 [1.27–1.57] and 1.96 [1.64–2.29]). After repeated administration, the accumulation ratios for AUC0–24, 24-hour concentration, and Cmax were 1.55, 1.57, and 1.38 for elbasvir and 2.03, 1.23, and 2.51 for grazoprevir. Co-administration of elbasvir 50 mg and grazoprevir 100 mg once daily did not have a clinically relevant effect on the PK variables of either drug. Median Tmax after co-administration versus alone was 3.0 hours versus 3.0 hours for elbasvir and 3.1 hours versus 3.0 hours for grazoprevir. Geometric mean ratios (90% CI) for elbasvir and grazoprevir AUC0–24 (Chinese/white participants) were 1.58 (1.03–2.42) and 1.21 (0.76–1.92). Elbasvir and grazoprevir, administered alone or concomitantly, were well tolerated.Implications
In healthy Chinese individuals, administration of elbasvir and grazoprevir, alone or concomitantly, was generally well tolerated, with a thoroughly characterized PK profile. Elbasvir and grazoprevir exposures may trend higher in Chinese healthy participants relative to white healthy participants. Protocol number MK-5172 PN022. 相似文献
1